⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2310225 | 0.73 | — | — | |
| SCHEMBL5151215 | 0.73 | — | — | |
| SCHEMBL2430393 | 0.71 | — | — | |
| SCHEMBL12724529 | 0.71 | — | — | |
| SCHEMBL11083228 | 0.71 | — | — | |
| SCHEMBL2310222 | 0.71 | — | — | |
| SCHEMBL9942584 | 0.71 | — | — | |
| SCHEMBL28845004 | 0.71 | — | — | |
| SCHEMBL11971227 | 0.68 | — | — | |
| SCHEMBL11955121 | 0.68 | DYRK1A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291535-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| CN-112601749-B | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment | 艾吉因生物股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20230279021-A1 | POLYMORPHS OF A GABAA ALPHA5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279021-A1 | POLYMORPHS OF A GABAA ALPHA5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230107032-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-06 | — | — | US | disclosed |
| US-11414425-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| WO-2022155419-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022011314-A1 | POLYMORPHS OF A GABAA α5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| EP-3810611-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | Agenebio, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-112601749-A | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment | 艾吉因生物股份有限公司 | 2021-04-02 | — | — | CN | disclosed |
| US-20200048268-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-13 | — | — | US | disclosed |
| US-20200048268-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-13 | — | — | US | disclosed |